Antifungal Tradecraft by Cholesterol Oxidase  by Nesbitt, Natasha M. & Sampson, Nicole S.
Normalized activities were analyzed
by a clustering statistical algorithm [9]
that segregated the enzymes into
four groups based on similar substrate
specificities. In an interesting twist
that sought relationships among sub-
strates in chemical space, correlations
between substrates were used to iden-
tify groups of substrates with similar
chimera profiles. This approach ad-
dresses whether a chimera’s activity
on one substrate predicts activity on
another with the outcome being the
identification of substrates that can
be surrogates for other substrates in
the same group. This classification
has the potential to facilitate discovery
of useful catalysts by high-throughput
screening using these surrogates. Not
too surprisingly, a correspondence
was found between the protein clus-
ters and the substrate clusters. The
analysis of the similarities and differ-
ences in physical, structural, and
chemical properties within and
between clusters—either protein or
substrate—should be a powerful tool
for gaining insight into P450 function
and for predicting the enzymatic activ-
ity of untested chimeras on tested
substrates and tested chimeras on
untested substrates. The authors use
their analysis to suggest that swap-
ping of the reductase domains always
resulted in functional enzymes be-
cause key interdomain interactions
were conserved.
The results illustrate that diversity in
sequence leads to diversity in func-
tion. The less expected, but more im-
portant finding is that such diversity in
function need not come at the ex-
pense of absolute activity. For all
eleven substrates, the top-performing
chimeric enzyme’s activity exceeded
that of the three parental enzymes.
However, the work most importantly
speaks to the power of directed evo-
lution approaches as a tool for not
just exploring, but for analyzing se-
quence space and its relationship
with functional space. Statistical
analysis of such combinatorial protein
engineering experiments, among
other approaches, will allow us to
move beyond simply cataloging pro-
tein space, but understanding it as
well.
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In this issue of Chemistry & Biology, Aparicio and coworkers report that secreted bacterial choles-
terol oxidase is required for the biosynthesis of the antifungal polyene pimaricin by Streptomyces
natalensis [1]. Their discovery expands the inventory of tasks this biotechnologically important
enzyme performs.Bacterial cholesterol oxidases have
been utilized by humans for more than
30 years to analyze the bane of West-
ern eating habits, serum cholesterol
[2–4]. For their own use, bacteria,
actinomycetes in particular, secrete
cholesterol oxidase to metabolize
3b-hydroxy sterols to 3-ketosteroids,
which serve as their energy source [5,
6]. Cholesterol oxidase, more properly
3b-hydroxysterol oxidase, is the first238 Chemistry & Biology 14, March 2007enzyme in that metabolic pathway
that yields propionate and acetate as
the ultimate products. Since their first
isolation, cholesterol oxidases have
been rediscovered in screens for in-
secticides [7], and have been widely
used in the search for lipid rafts [8]. In
the presence of a sufficient quantity of
either cholesterol or ergosterol mixed
with saturated lipids, liquid-phase
membranes are ordered, that is, theyª2007 Elsevier Ltd All rights reservedcan form lipid rafts. Oxidation of the
sterol to cholest-4-en-3-one or ergo-
sta-4,7,22-trien-3-one (Figure 1) re-
sults in dissolution of these lipid
domains. These liquid-disordered
membranes render the lipid bilayer
more permeable and susceptible to ly-
sis, which is the mechanism of insecti-
cidal activity [9].
Now, Aparicio and coworkers report
a new function for the Streptomyces
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PreviewsFigure 1. The Reaction Catalyzed by 3b-Hydroxysterol Oxidases
In the reaction catalyzed by cholesterol oxidase, the 3b-hydroxysterol (cholesterol or ergosterol) is
oxidized and isomerized to an a,b-unsaturated ketone.natalensis cholesterol oxidase PimE
[1]. The pimE gene resides in the cen-
ter of the pimaricin polyketide biosyn-
thetic cluster in the S. natalensis ge-
nome. It has been a mystery whether
its residence in the gene cluster was
an accident of evolution or a conse-
quence of a functional role in pimaricin
biosynthesis, since the synthesis of
the polyketide does not require cho-
lesterol oxidation. The authors discov-
ered that disruption of the pimE gene
inhibits pimaricin production, suggest-
ing that the gene has a functional role
in antifungal biosynthesis.
Cholesterol oxidases catalyze the
FAD-dependent oxidation of a 3b-
hydroxy sterol to a 3-keto steroid and
hydrogen peroxide. The b,g-unsatu-
rated ketone intermediate undergoes
a 1,3 allylic isomerization to form an
a,b-unsaturated ketone (Figure 1).
Detailed kinetic analysis and site-
directed mutagenesis have identified3 active site residues, His, Glu, and
Asn, as important for oxidation and
isomerization [10, 11]. The proposed
functions of these amino acids in catal-
ysis is supported by crystallographic
analysis [12–14] and homology with
other members of the glucose-metha-
nol-choline (GMC) oxidoreductase
family [15]. The primary amino acid se-
quence of PimE has a high percent
identity (59%–91%) with known cho-
lesterol oxidases. Among the con-
served amino acids are the essential
His, Glu, and Asn, as well as the con-
sensus sequence for binding of the
flavin cofactor.
Aparicio and coworkers isolated
and purified PimE from S. natalensis
culture filtrates and demonstrated
that it is truly an extracellular choles-
terol oxidase [1]. The enzyme pro-
duces hydrogen peroxide and choles-
tenone with a catalytic efficiency
consistent with it being a cholesterolChemistry & Biology 14, March 2007 ªoxidase, and it has a molecular mass
consistent with that predicted for the
mature PimE according to SDS-
PAGE analysis. Although no spectral
data were presented, it is presumed
that a flavin cofactor is bound to the
protein, as the sequence homology
for the flavin-binding domain is high.
The authors disrupted the pimE gene
and found that culture broths of the
mutant (S. natalensis D3) were unable
to catalyze cholesterol oxidation. Un-
expectedly, pimaricin production was
blocked in the mutant strain. No pimar-
icin could be isolated from culture
filtrates nor was antifungal activity
against Candida utilis observed
(Figure 4 in [1]).
Cholesterol oxidase activity and pi-
maricin production were restored in
the S. natalensis D3 mutant comple-
mented with a vector containing pimE
and its putative promoter. More sur-
prisingly, adding purified PimE protein
to the D3 mutant cultures restored pi-
maricin biosynthesis. Moreover, other
commercially available cholesterol ox-
idases restored pimaricin production
in the D3 mutant. Interestingly, the
cholesterol oxidase from Pseudomo-
nas (now Burkholderia cepacia [16]),
that is not a member of the GMC
oxidoreductase family and does not
share sequence or structural homol-
ogy, complemented the mutant very
poorly. The weak complementation
suggests that the protein’s structure
may be important for pimaricin
induction.
The precise mechanism by which
extracellular PimE induces pimaricin
biosynthesis remains to be elucidated.
Transcriptional regulation of the pi-
maricin cluster was ruled out as tran-
scription of the cluster genes was not
affected by pimE deletion [1]. Thus, it
appears that PimE controls either
translation of the pim gene cluster or
secretion of pimaricin. Two mechanis-
tic models for upregulation of pimarcin
production seem plausible. First, the
product generated by PimE may be
the pimaricin inducer, or second,
PimE itself may activate pimaricin
production by acting as a ligand for
a receptor signaling system.
The authors further investigated the
importance of sterol oxidation for
polyketide production. Addition of the2007 Elsevier Ltd All rights reserved 239
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(H2O2 and cholest-4-en-3-one) to the
D3 mutant did not induce pimaricin
production. However, preincubation
of PimE with cholesterol or ergosterol
before addition to D3 cultures sup-
pressed PimE’s induction of pimaricin
biosynthesis. Furthermore, inhibition
of PimE catalytic activity with HgCl2
or AgNO3 before addition to D3 cul-
tures also prevented pimaricin pro-
duction. The exact mechanism of
PimE inactivation is unknown—per-
haps oxidation of a cysteine or methio-
nine blocks substrate binding [17].
The authors’ experiments suggest
that sterol oxidation products are not
directly involved in pimaricin produc-
tion, yet oxidase activity is required
for induction. There are caveats to
these experiments, and additional
work is required to fully understand
the regulatory mechanism. For exam-
ple, the relative substrate specificities
of PimE for different sterols have not
been assessed under physiological
conditions, and the identity of the true
substrate is not yet known. The physio-
logical PimE product may be ergosta-
4,7,22,trien-3-one or an as yet uniden-
tified ketone product. Consequently,
addition of the correct product could
potentially induce pimaricin produc-
tion. Moreover, addition to bacteria of
product solubilized in a detergent mi-
celle, as Aparicio and coworkers did
[1], may have a very different effect
than direct formation of the product in
the bacterial membrane. Interestingly,
D3 cultures grown in mineral medium
lacking possible sterols still produced
pimaricin when complemented with
PimE, albeit at very low levels com-
pared to complementation of D3 cul-
tures grown in yeast/malt extract.
PimE induction of pimaricin biosynthe-
sis in yeast-free media argues against
the sterol product hypothesis. How-
ever, there is a possibility that a suffi-
cient quantity of sterol copurified with
the enzyme when it was isolated from
S. natalensis cultures to account for
the low level of pimaricin production.
The alternative to pimaricin induc-
tion by the PimE reaction product is
a receptor-mediated signaling mecha-
nism. In this mechanism, binding of the
PimE protein to a receptor in theStrep-
tomyces cell wall would initiate a signal240 Chemistry & Biology 14, March 2007to produce pimaricin. As no direct
evidence for a PimE receptor has yet
been obtained, the type of signaling
molecules that might be involved are
unknown. Additionally, signaling by
PimE could require that a ligand be
bound to the enzyme, e.g., a sterol or
another unknown compound. The low
complementation activity by the struc-
turally distinct Pseudomonas (Burkhol-
deria) cholesterol oxidase supports
the receptor hypothesis.
A mechanism featuring PimE as
a sterol sensor is appealing, and sens-
ing could be operating in either model.
Streptomyces do not typically have
sterols in their membranes. However,
the presence of a fungal competitor,
e.g., Candida, may result in transfer
of ergosterol or some other sterol into
the Streptomyces membrane. Per-
haps the presence of ergosterol is
a signal to Streptomyces to initiate
PimE expression, and thus, polyketide
production. Even more speculatively,
the expression of PimE could serve
the dual purpose of membrane struc-
ture modulation and stimulation of pi-
maricin production. If fungal sterols
were incorporated into the Streptomy-
ces membrane, they would rigidify it
and interfere with secretion and/or sig-
naling. Oxidation of sterol would help
restore the correct fluidity to the mem-
brane. Linking pimaricin production to
sterol sensing is attractive because the
polyene macrolide interacts with er-
gosterol in the fungal membrane [18].
Thus, pimaricin biosynthesis would
only occur if the direct target, ergos-
terol, were present.
Identification of the environmental
signal(s) that induces PimE expression
is key to understanding PimE function.
The expression of all previously identi-
fied cholesterol oxidases is induced by
the presence of 3b-hydroxysterol in
the culture medium. If PimE expres-
sion is sterol-induced, this finding will
provide strong support for an environ-
mental sensing role for PimE. PimR
has been identified as a positive regu-
lator of pimaricin biosynthesis and
pimE transcription [19]. However,
what regulates PimR and its relation-
ship to pimE are unclear.
Aparicio and colleagues present in-
triguing data that an extracellular en-
zyme induces polyketide biosynthesis.ª2007 Elsevier Ltd All rights reservedPutative cholesterol oxidases have
been identified within the biosynthetic
gene clusters of the antifungal polyke-
tides filipin (pteG) and CE-108/rimoci-
din (rimD) [20, 21] produced by other
Streptomyces strains. All of these
polyketides are elicited against fungi,
whose membranes are distinctly dif-
ferent than bacterial membranes by
virtue of their ergosterol content, mak-
ing the pimaricin regulatory model an
attractive paradigm that may be more
widely utilized. It will be exciting to
watch the cholesterol oxidase story
continue to unfold and to learn the mo-
lecular details of antifungal biosynthe-
sis regulation.
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In a recent issue ofChemistry & B
to identify b-hexosaminidase inh
drug candidates for the treatmen
Genetic conformational diseases are
often caused by modest mutations in
proteins that lead to unnecessary
recognition of the mutant protein by
the endoplasmic reticulum (ER) quality
control systemasmisfolded. These mu-
tations classically occur outside of the
predicted functional domain of the af-
fected proteins such that interventions
to allow their release from the quality
control system and their targeting to
their proper site of action could restore
function [2]. Classic examples of such
diseases include cystic fibrosis, neph-
rogenic diabetes insipidus, hypogona-
dotropic hypogonadism, and various
lysosomal storage disorders such as
GM2 gangliosidosis, Fabry, Gaucher,
and Morquio B diseases.
Pharmacological chaperones are
small molecules that can bind and sta-
bilize the folding intermediates of the
mutant proteins thus favoring their
proper folding, ER export, and subse-
quent trafficking to their normal sub-
cellular location [3]. In most instances,
pharmacological chaperones that can
rescue folding, trafficking, and func-
tion of mutant proteins have been
found among ligands that were already
known to bind to the affected proteins
thus conferring a measure of selectiv-
ity. For example, specific receptor
antagonists in the case of diseases19. Anton, N., Mendes, M.V., Martin, J.F., and
Aparicio, J.F. (2004). J. Bacteriol. 186,
2567–2575.
20. Omura, S., Ikeda, H., Ishikawa, J., Hana-
moto, A., Takahashi, C., Shinose, M.,
Takahashi, Y., Horikawa, H., Nakazawa,r Promotes Activi
rch in Immunology and Cancer, Marcelle-Co
anada
eal.ca
iology, Tropak et al. [1] reported a h
ibitors that act as pharmacologica
t of Tay-Sachs disease.
resulting from mutations in G protein-
coupled receptors (like V2-vaso-
pressin and gonadotropin-releasing
hormone receptors for nephrogenic
diabetes insipidus and hypogonado-
tropic hypogonadism, respectively
[4,5]) and competitive enzyme inhibi-
tors for lysosomal storage disorders
[6] were found to increase the levels
of active receptors and enzymes in
cellular systems, indicating that such
compounds could have therapeutic
value. Consistent with this notion,
a small scale clinical trial carried out
in nephrogenic diabetes insipidus
patients confirmed the therapeutic
activity of a pharmacological chaper-
one, as administration of a vasopressin
antagonist significantly improved kid-
ney functions in five patients harboring
three distinct mutations [7].
The use of an antagonist or inhibitor
to treat a disease resulting from a loss
of function mutation may appear con-
tradictory, but is based on the idea
that the high affinity binding of these
compounds to the mutant protein
provides sufficient interaction time to
promote proper folding and escape
from the ER quality control system.
Obviously, the inhibitors then need to
dissociate from the rescued enzyme/
receptor to permit their activity. It fol-
lows that detailed pharmacokinetic
Chemistry & Biology 14, March 2007 ª2H., Osonoe, T., et al. (2001). Proc.
Natl. Acad. Sci. USA 98, 12215–
12220.
21. Seco, E.M., Perez-Zuniga, F.J., Rolon,
M.S., and Malpartida, F. (2004). Chem.
Biol. 11, 357–366.ty
utu Pavillion, C.P. 6128 Succursale
igh-throughput screening assay
l chaperones and are potential
studies are needed to find a drug ad-
ministration regimen that would result
in the optimum therapeutic activity
of individual pharmacological chaper-
ones.
Based on the idea that inhibitors can
act as pharmacological chaperones
and rescue the activity of protein func-
tion, Tropak et al. [1] developed a real
time, high-throughput assay to identify
new inhibitors of human b-hexosami-
dase that could have pharmacolog-
ical activity in the treatment of two
forms of GM2 gangliosidosis, infantile
Tay-Sachs disease (ISD) and adult
Tay-Sachs disease (ATSD). These
diseases result from mutations in
the gene encoding b-hexosaminidase
that render the enzyme unstable
most likely due to misfolding, thus
making them potential targets for the
therapeutic action of pharmacological
chaperones. The fluorescence-based
in vitro assay developed by the authors
uses purified enzyme and identified 24
confirmed inhibitors of the enzymatic
activity out of a commercially available
50,000 compound library. Three of
these compounds, belonging to dis-
tinct classes of chemical structures,
were then selected to study their
potential action as pharmacological
chaperones in treatment of Tay-Sachs
disease.
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